Hasil Similarity Cek_The effects of dosage variation in black cumin seed oil (Nigella sativa L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome

Agustiarini, Vitri and Darmawan, Endang and Akrom, Akrom (2019) Hasil Similarity Cek_The effects of dosage variation in black cumin seed oil (Nigella sativa L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome. Pharmaciana, 9 (2). ISSN ISSN:2088-4559,e-ISSN:2477-0256 (Unpublished)

Text HASIL CEK_Darmawan, Akrom_metabolic syndrome, BCSO, HbA1c, IL-17A (1).pdf Download (2MB)

Abstract

Metabolic syndrome causes an imbalance of the immune system and increased levels of HbA1c
and IL-17A expression. Black cumin seed oil (BCSO) is known to have antioxidant and
immunomodulatory properties. This study reports the effects of dosage variation in BCSO (1.5 and 3
ml per day for 20 days) on HbA1c levels and IL-17A expression in patients at risk of metabolic
syndrome at Jetis 1 Public Health Center in Bantul, Yogyakarta. It employed a crossover design in
which a total of 66 patients at risk of metabolic syndrome were divided into two groups receiving a
sequence of different treatments. Group 1 (N=33) received treatment A first, which was BCSO at a
dose of 1.5 ml/day for 20 days. Then, after a washout period of 7 days, it received treatment B, 3 ml of
BCSO per day for 20 days. Group 2 followed the same procedure only vice versa, treatment B, then A.
The HbA1c levels were measured by the mean plasma glucose (MPG) method, while the IL-17A
expression was detected by flow cytometry. The average HbA1c level and IL-17A expression of the
treatment groups were statistically analyzed with 95% confidence level. In response to the treatment
regime, the HbA1c level of group 1 was 7.34 ± 2.51% (a decrease), and that of group 2 was 7.72 ±
2.44% (an increase). The IL-17 expression in group 1 was 3.74 ± 3.52% (a decrease), and the one in
group 2 was 4.07 ± 3.65% (an increase). The effects of administering 1.5 ml and 3 ml BCSO per day
for 20 consecutive days on Hb1c level (p=0.17) and IL-17A expression (p=0.67) were not significantly
different. Most patients experience a decrease in HbA1c levels and IL-17A expression after the
treatment. Insignificant differences between the two groups mean that at the doses of 1.5 ml/day and 3
ml/day for 20 days, BCSO exhibits the same effects in patients at risk of metabolic syndrome
registered at Jetis 1 Public Health Center in Bantul, Yogyakarta.

Item Type:	Artikel Umum
Subjects:	Z Bibliography. Library Science. Information Resources > Z665 Library Science. Information Science
Divisi / Prodi:	Faculty of Pharmacy (Fakultas Farmasi) > S1-Pharmacy (S1-Farmasi)
Depositing User:	Akrom Akrom
Date Deposited:	21 Jun 2022 02:05
Last Modified:	21 Jun 2022 02:08
URI:	http://eprints.uad.ac.id/id/eprint/35452

Actions (login required)

View Item